GSK Gets under Your Skin - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

GSK Gets under Your Skin
A recent deal could chart new paths in drug delivery and in the administration of vaccines.


Pharmaceutical Technology
Volume 34, Issue 1, pp. 14

Despite, or because of, economic difficulties and meager pipelines, the recent past has seen many drug companies investigate alternative delivery methods for their products. A new deal between GlaxoSmithKline (London) and Intercell (Vienna) reflects this trend and raises hopes for the development of innovative routes of administration.

The two companies will work to bring needle-free vaccines, based on Intercell's technology, to market. Intercell's Vaccine Patch is a transcutaneous method of delivering adjuvant and antigen directly to the immune system. The adjuvant passes through the skin's stratum corneum and spurs cells of the immune system to take up the antigen and bring it to the lymph nodes. The Vaccine Patch contains the enterotoxin from Escherichia coli, an adjuvant and a powerful stimulator of the immune system. The companies believe that the technology could make vaccinations easier and more efficient.

They also hope to use Intercell's technology to improve patients' immune response to existing injected pandemic influenza vaccines. Intercell is developing a Vaccine Enhancement Patch that, in studies, has resulted in a seroconversion rate (i.e., the concentration of antibodies) of 70% after a single dose.

If the technology proves sound, the Vaccine Patch could open the door to the development of vaccines that can't safely be administered through injection, and it could certainly boost compliance among needlephobes. The deal may be a sign that a wider array of biologicals will soon be available for transcutaneous delivery.

Erik Greb is an assistant editor of Pharmaceutical Technology.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here